Sanofi invests to make France its world class center of excellence in vaccine research and production

SanofiSanofi detailed plans on how the Company will make significant investments in France to increase its vaccines research and production capacities, and contribute in responding to future pandemic risks. Aligned with its corporate strategy presented last December, Sanofi will invest €610 million to create a new production site and research center in France with both dedicated to vaccines.

"Sanofi's heart beats in France. We have a long history and exceptional teams working throughout the country, embodying our strong values. By investing in a new industrial site and a R&D center, Sanofi positions France at the core of its strategy, aiming to make France a world-class center of excellence in vaccine research and production," said Paul Hudson, Chief Executive Officer at Sanofi. "Sanofi is a major healthcare player in France, in Europe, and worldwide. It is our responsibility to focus our resources and expertise against the current pandemic, but also to invest in preparing for future ones. We welcome the ongoing collaboration and commitment of the French authorities who we have been working alongside with the last several months to achieve this."

Sanofi will invest in vaccine production in France and create its Evolutive Vaccine Facility (EVF) in Neuville sur Saône. This state-of-the-art industrial site will utilize the latest innovative vaccine production technologies. The project represents an investment of €490 million over a five-year period, and is expected to create 200 new jobs. Sanofi’s investment has been made possible thanks to the support and the close collaboration with French authorities over the last few months.

The building of this plant will enable Sanofi Pasteur, Sanofi's global entity dedicated to vaccines, to be the first pharmaceutical manufacturer to benefit from such an industrial tool and to secure vaccine supplies in the event of new pandemics. EVF is a new type of factory designed around a central unit housing several fully digital production modules that make it possible to produce three to four vaccines simultaneously, versus only one in current industrial sites. This modularity will make it possible to prioritize the production of a specific vaccine in a more timely manner based on public health issues.

Sanofi has also committed to investing €120 million to create a new R&D center in France at the Sanofi Pasteur site in Marcy-l'Etoile to develop future vaccines. This state-of-the-art digital facility will house highly specialized laboratories that will enable the development of vaccines against emerging diseases and pandemic risks. The facility will become a world reference for pre-clinical research and pharmaceutical and clinical development. Sanofi expresses its gratitude to the Auvergne-Rhône-Alpes French region for its support in this project.

Sanofi shares the French authorities’ vision for a sovereign Europe in healthcare and announced last February the creation of a new industry-leading European company to provide active pharmaceutical ingredients. The company today stands ready to cooperate with France and the European Union (EU) on other projects which will provide the EU with extra vaccine (EVF extension project) or monoclonal antibody (cell culture tanks installation and start-up project) production capabilities. These supplementary capabilities can be leveraged by the EU and other pharma companies in the event of a healthcare crisis.

A world leader in vaccines

Sanofi, with its global vaccine entity Sanofi Pasteur, is a leading vaccine developer and manufacturer. Sanofi offers a portfolio of vaccines to protect children, adolescents, and adults from diseases such as influenza, infectious diseases, and endemic diseases.

With 16,000 employees and an international network of 12 industrial sites dedicated to vaccine manufacturing, including three in France (Marcy-l'Etoile, Neuville sur Saône, Val-de-Reuil), Sanofi Pasteur’s vaccines protect more than half a billion people in the world.

Sanofi is the world's third largest vaccine producer in value terms, with a unique footprint in the Rhône-Alpes region and nearly 7,200 employees working for the Sanofi Pasteur site in Lyon, a global center of excellence in the field of vaccines.

A major player in the healthcare sector in France

Sanofi plays a major role in meeting the health needs of patients and supporting their healthcare. In France, Sanofi provides more than 200 medicines, vaccines, and health products.

With a unique footprint of 33 sites in France, including 22 industrial sites and approximately 25,000 employees, Sanofi represents a quarter of the workforce of the entire French pharmaceutical industry.

Sanofi is France's leading private R&D investor, with more than €2 billion spent each year researching new treatments for patients, totaling half of the private research effort in France. Nearly 5,000 researchers and scientists work in a variety of therapeutic areas, mainly focusing on oncology, immuno-oncology, vaccines and rare diseases.

Sanofi also has one third of its global production in France, making it one of the country’s leading exporters. Sanofi has invested €3 billion in its French production sites over the past five years, including €1.5 billion to accelerate the build-up of biotechnologies in the country.

On the front line in the fight against COVID-19

Since the beginning of the pandemic, Sanofi has played a leading role in the fight against COVID-19. In collaboration with health authorities and international partners, Sanofi is one of the only companies in the world to work on the search for COVID-19 vaccine candidates by exploring two different technological approaches.
  • The recombinant DNA technology, in collaboration with GSK, is a type of vaccine that makes it possible to industrially produce very large quantities of antigens, the proteins injected to stimulate the immune system’s response to the virus.
  • The messenger RNA technology technology, in collaboration with TranslateBio, is a vaccine that leads the human body’s cells to manufacture the virus antigens to which the immune system will react.

Sanofi is also committed to making its vaccine accessible to all and around the world.

About Sanofi

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Most Popular Now

73,000 Scientists collaborate over new COVID-19 Da…

More than 73,000 users collaborate on new online platform set up by the European Open Science Cloud Initiative, where scientists share COVID-19 data and accelerate our un...

Antiviral used to treat cat coronavirus also works…

Researchers at the University of Alberta are preparing to launch clinical trials of a drug used to cure a deadly disease caused by a coronavirus in cats that they expect ...

Search for COVID-19 drugs boosted by SARS discover…

An extensive search and testing of current drugs and drug-like compounds has revealed compounds previously developed to fight SARS might also work against COVID-19. Us...

Pfizer and BioNTech share positive early data on l…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) shared additional Phase 1 safety and immunogenicity data from their ongoing U.S. study of the BNT162 mRNA-based vac...

Phase I clinical trial initiated for monoclonal an…

The first participants have been dosed in a Phase I trial of AZD7442, a combination of two monoclonal antibodies (mAbs) in development for the prevention and treatment of...

Europe's largest initiative launches to accelerate…

CARE (Corona Accelerated R&D in Europe) a new consortium supported by the Innovative Medicines Initiative (IMI) public-private partnership announced its launch to acceler...

Vitamin D deficiency may raise risk of getting COV…

In a retrospective study of patients tested for COVID-19, researchers at the University of Chicago Medicine found an association between vitamin D deficiency and the like...

Blocking cellular communication stops SARS-CoV-2

In the transmission of signals within the cell which, for example, stimulate cell growth or trigger metabolic processes, phosphate groups play an important biochemical ro...

Improving FDA's COVID-19 vaccine authorization and…

On March 28, the Food and Drug Administration (FDA) exercised its Emergency Use Authorization (EUA) authority to allow the use of hydroxychloroquine for the treatment of ...

Steroid found to improve survival of critically il…

A new international study published today has shown that treating critically ill patients with COVID-19 with the steroid hydrocortisone improves their chances of recovery...

Bayer and Informed Data Systems Inc. (One Drop) jo…

Bayer and Informed Data Systems Inc. (One Drop), a US-based digital health company, today announced that they have entered into an agreement to jointly develop digital he...

Abbott's fast, $5, 15-minute, easy-to-use COVID-19…

Abbott (NYSE: ABT) announced that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for its BinaxNOW™ COVID-19 Ag Card rapid test f...